+many on W2R's input. Many to most MS therapies do not survive the scrutiny of well designed clinical trials.
I would add that the measurements of statistical significance of several of the the approved therapies aren't very strong either.
A quote taken right from the article:
We can't give the illusion to patients that this is a guaranteed treatment and it is easy. This is not right. And we have never done this," says Hilarescere President Fabio Roversi-Monaco. "We don't say this is a cure for M.S. We only say that research is advancing, and there is encouraging data but we are waiting for more conclusions
I personally suspect that R&D funding into hard to treat syndromes like MS will suffer greatly in the next few years to the extent that the potential profit from marketing treatments comes under increasing attack from so-called health care reform efforts. Its quite reasonable to provide everyone with basic care at a reasonable cost, its sad that this appears to go hand in hand with eviscerating our ability to tackle more complex maladies.
A reputable website to read about the status of emerging treatments for MS is mspipeline